Boji Medical Technology Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Boji Pharmaceutical Technology Co., Ltd. (referred to as "Boji Pharmaceutical", stock code 300404), founded in 2002 and listed on the Shenzhen Growth Enterprise Market in 2015, is a new high-tech enterprise (CRO+CDMO) that provides one-stop outsourcing services for the entire process of research and development and production of drugs, medical devices, and health products for domestic and foreign pharmaceutical enterprises. The company is headquartered in Smart City, Tianhe District, Guangzhou, with a modern office space of nearly 51000 square meters, bringing together nearly 800 experienced, knowledgeable, and agile mid to senior medical research talents and registered regulatory experts. The company has nine wholly-owned subsidiaries with different business expertise and more than ten holding and participating companies. Boji Pharmaceutical's "one-stop" services include: new drug project research and activity screening, pharmaceutical research (raw materials, formulations), drug evaluation (pharmacodynamics, toxicology), integrated small molecule innovative drug services, clinical research, Sino US dual reporting (registration services), CDMO production (MAH landing), and technological achievement transformation, covering all stages of new drug development. Clinical research is one of the company's core businesses, covering the registration research and post market re evaluation of drugs, medical devices and health products, as well as specialty medical foods. Especially skilled in clinical research of innovative drugs and medical devices. The service content includes the entire process of clinical trials, including clinical research protocol writing, clinical monitoring, SMO (CRC service), data management and statistical analysis, BE testing, subject recruitment, third-party auditing, etc; The treatment field covers almost all professional treatment fields. In addition to the company headquarters, there are clinical research subsidiaries and nearly 40 domestic clinical monitoring networks in Beijing, Shanghai, Nanjing and other places. Pharmaceutical research has an excellent research and development team, and has established a complete CNAS quality assurance system to provide customers with research and development services such as chemical raw materials and preparations, traditional Chinese medicine, and biopharmaceutical processes, quality standard research, etc. It can not only develop generic and improved innovative drugs, but also independently develop Class 1 innovative drugs for customers. The center has a Chemical and Pharmaceutical Research Department, a Traditional Chinese Medicine Research Department, and a Biological Products Research Department. It has established service platforms such as a new technology research and development platform for formulations (sustained and controlled release, injections, inhalation formulations, topical formulations, etc.), a protein based biological product research and development platform, a peptide based drug research and development platform, a traditional Chinese medicine compound and active component research and development platform, and a generic drug consistency evaluation center. The Drug Evaluation Center is a technical service platform created by the company for innovative drug efficacy and safety research. It has passed the national GLP certification and obtained the GLP certificate. The center currently has nearly 6000 square meters of animal laboratories and auxiliary facilities, nearly 30 million advanced instruments and equipment, and can simultaneously carry out more than 10 new drug evaluations. The center has eight departments and two committees, including the Pharmacology Department, Toxicology Department, Quality Assurance Department, Experimental Animal Department, and Experimental Animal Ethics Committee. It has a comprehensive quality assurance system and a strong research team; We have rich research experience in the screening and evaluation of drug efficacy in chemical, biopharmaceutical, traditional Chinese medicine, and medical devices, as well as non clinical safety evaluation (including pre testing) of drugs, and pharmacokinetic research. CDMO production is undertaken by Guangzhou Boji Biomedical Technology Park Co., Ltd. The registered capital of the technology park is 130 million yuan, covering an area of 33000 square meters. The first phase has built 7 incubators and GMP production platforms exceeding 20000 square meters, including quality inspection, office buildings, solid preparation workshops (tablets, hard capsules, granules, powders), traditional Chinese medicine extraction workshops, chemical raw material medicine workshops, as well as supporting facilities such as fire protection, environmental protection, and power; The service content includes the landing of MAH, process amplification research, clinical trial drug production, simulation agent research and production, project registration registration, and new drug project investment and financing. Since its establishment, Boji Pharmaceuticals has always adhered to the business philosophy of "honesty, trustworthiness, professionalism, and authority". As of September 30, 2019, the company has provided more than 500 clients with over 500 pre clinical research services and over 700 clinical research services, covering various professional fields of drug treatment, including more than 60 innovative drugs with high difficulty. Through the clinical research services provided by the company, it has helped clients obtain more than 60 new drug certificates, There are approximately 100 production batches.After 18 years of development, Boji has developed into one of the few CROs that can provide one-stop full process services. It can fully utilize the synergistic effects of various business sectors to complete a full process service of new drugs from pharmacy, efficacy, toxicology, clinical application, and contract production, saving research and development costs, communication costs, and time for customers. In terms of technical strength, service quality, and service scope Team building and other aspects are at the forefront of the domestic CRO industry, becoming a leading enterprise for local CRO companies in China. |
| Headquarter | Guangzhou |
| Establish Date | 9/29/2002 |
| Listed Code | 300404.SZ |
| Listed Date | 4/24/2015 |
| Chairman | Wang Tingchun. |
| CEO | Wang Tingchun. |
| Website | www.gzboji.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
